The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation (DUET)
The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]
Sponsor: Alexion Pharmaceuticals, Inc.
A PHASE3 clinical study on Antibody-mediated Rejection and Cardiac Allograft Vasculopathy, this trial is completed. The trial is conducted by Alexion Pharmaceuticals, Inc. and has accumulated 11 data snapshots since 2012. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Dec 2023 [monthly]
Completed PHASE3
-
Jun 2021 — Apr 2023 [monthly]
Completed PHASE3
Phase: PHASE4 → PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE4
Status: Enrolling By Invitation → Active Not Recruiting
-
Aug 2018 — Sep 2019 [monthly]
Enrolling By Invitation PHASE4
-
Jun 2018 — Aug 2018 [monthly]
Enrolling By Invitation PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE4
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharmaceuticals, Inc.
- Cedars-Sinai Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .